DUBLIN–(BUSINESS WIRE)–The “Global Radiotheranostics Market by Radioisotope, Application, End-user and Region: Competition Forecast and Opportunities to 2027” report has been added to ResearchAndMarkets.com’s offering.
The Global radiotheranostics market is anticipated to register growth at an impressive CAGR in the forecast period, 2023-2027. Radiotheranostics is a process that involves the use of radionuclides for paired imaging and therapy agents. It is a systematic integration of targeted diagnostics and therapeutics.
The growing prevalence of cancer and the rising adoption of injectable radiopharmaceuticals that have antitumor effects are majorly contributing to the global radiotheranostics market growth. The increasing usage of radiotheranostics in cancer diagnosis and management is providing a thrust to the market. Radiotheranostics have enhanced therapy efficacy, the ability to manage adverse and critical health situations, which results in improved patient outcomes.
Moreover, the recent research and developments in the radiotheranostics field is creating a positive impact on the market growth. For instance, there have been major outcomes in radiotheranostics for prostate cancer and neuroendocrine tumors. Additionally, the regulatory approval of numerous radiotheranostics pairs is expected to boost their adoption for cancer treatments.
For instance, the approvals of new radiotheranostics agents such as 177Lu-PSMA-617 and 177Lu-DOTATATE have resulted in the resurgence of research in the field of radiotheranostics and have proliferated the number of clinical trials and testing several other novel radiotheranostics.
Furthermore, the continuous support in research and development to keep pace with current momentum in radiotheranostics innovations is supporting the market growth. Additionally, the clinical use of radiotheranostics agents have increased dramatically due to the successful strides that have been made in the understanding of underlying biology of cancer and enhanced methods for synthesizing and designing targeted theragnostic agents. This, in turn, is positively influencing the market growth.
Structural imaging is the most crucial component of staging, diagnosing, and assessing responses in cancer patients. However, patients and healthcare professionals are increasingly seeking non-invasive methods of investigating tumor phenotypes and assessing molecular and functional responses to therapy. Therefore, radiotheranostics, a combination of non-invasive diagnostic imaging with targeted therapy, is widely being implemented. As a result, the global market for radiotheranostics is anticipated to propel at a rapid pace in the coming years.
Companies Mentioned
- TransCode Therapeutics, Inc.
- Curium SAS
- GE Healthcare Inc.
- Bayer AG
- Lantheus Medical Imaging, Inc.
- Novartis AG
- Spectrum Pharmaceuticals, Inc.
- Ipsen S.A.
- Actinium Pharmaceuticals, Inc. (ATNM)
- Nordic Nanovector ASA
- Y-mAbs Therapeutics, Inc.
- Sofie Biosciences, Inc.
- Terumo Corporation
- Sirtex Medical Limited
- Boston Scientific Corporation
Report Scope
In this report, global radiotheranostics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Global Radiotheranostics Market, by Radioisotope:
- Technetium-99
- Gallium-68
- Iodine-131
- Iodine-123
- 18F
- Y-90
- Lutetium (Lu) 177
- Copper (Cu) 67
- Copper (Cu) 64
- Others
Global Radiotheranostics Market, by Application:
- Oncology
- Non-Oncology
Global Radiotheranostics Market, by End-user:
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Others
Global Radiotheranostics Market, by Region:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- South America
For more information about this report visit https://www.researchandmarkets.com/r/3aj9dj
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900